Abstract
Background
HER2-targeted antibody–drug conjugates were recently approved in China for treatment of advanced or metastatic urothelial carcinoma (UC). We summarise emerging evidence supporting use of HER2-targeted regimens in patients with localized disease.
Methods
We searched MEDLINE, Embase, Web of Science, CENTRAL through March 29, 2026, and SinoMed, Wanfang and CNKI through October 14, 2025 to identify studies evaluating HER2-targeted therapies, in patients with localized UC. Random-effects meta-analyses pooled response rates, including pathological complete response (pCR). Clinical complete response (cCR) was stratified by response definition. Heterogeneity was assessed using Cochrane's Q test. Risk-of-bias (RoB) was assessed using ROBINS-I tool. The study was registered prospectively (CRD420250650326).
Results
Thirty-three studies comprising 970 patients were included (17 prospective); 30 tested disitamab vedotin (DV). In 13 studies testing DV-containing regimens as neoadjuvant therapy, the pooled pCR rate was 48% (95% CI 39–58%, N = 398; 54% among surgery-evaluable patients). Evidence was insufficient to establish an association between HER2 expression and pCR (risk ratio [RR] 0.82, 95% CI 0.52–1.29; p = 0.38; N = 72). In bladder-sparing studies, cCR was 65% (95% CI 44–82%) with definitions requiring complete absence of residual tumor and 54% (95% CI 41–67%) with definitions permitting residual Ta/Tis disease. Among included trials using DV, rate of grade ≥3 adverse events did not exceed 35% and was lower than that reported in studies evaluating other HER2-targeted agents. Major RoB concerns regarded outcome measurement as none of included trials was blinded.
Conclusions
DV-containing regimens show promising activity as neoadjuvant therapy in patients with bladder cancer. Current evidence is insufficient to establish an association between HER2 expression and response. Emerging data indicate possible role in bladder-sparing setting with low rates of toxicity and no G5 safety signals, although heterogeneous cCR definitions limit interpretation.
Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1007/s00345-026-06868-2.
Keywords: HER2, Disitamab vedotin, Antibody–drug conjugate, Urothelial carcinoma, Neoadjuvant therapy
Background
Neoadjuvant systemic therapy is standard of care (SOC) in patients with muscle-invasive bladder cancer (MIBC). This approach was developed with chemotherapy [1], but even with modern platinum-based regimens, the rates of pathologic complete response (pCR) are modest [2]. The NIAGARA trial introduced a practice-changing “sandwich” approach, adding durvalumab to standard-of-care chemotherapy, while CheckMate 274 [3] and AMBASSADOR [4] proved efficacy of adjuvant immune checkpoint inhibitor (ICI) treatment with nivolumab and pembrolizumab, respectively. ICIs with chemotherapy also provide favorable results in the neoadjuvant setting, with over twofold higher rates of pCR compared to chemotherapy alone, though with an uncertain impact on mortality [5]. Recently, a major breakthrough was introduced by the KEYNOTE−905 study for cisplatin-ineligible patients. Enfortumab vedotin (EV), an antibody–drug conjugate (ADC), combined with pembrolizumab (P) led to pCR in over half of the patients and a twofold improvement in overall survival (OS), followed by a FDA approval of EV+P as perioperative therapy for platinum-ineligible patients [6]. Additionally results of treatment with EV+P in cisplatin-eligible population showed over 20% improvement in rate of pCR compared with chemotherapy [7]. There is a clear shift towards molecularly targeted ADCs or ICIs in MIBC treatment paradigms; however, these highly molecularly precise agents are being used in all-comers, with little personalization of treatment beyond “cisplatin-eligibility”.
The mutation in the ERBB2 gene encoding human epidermal growth factor receptor 2 (HER2), as well as simply overexpression of the receptor has been associated with tumorigenesis, disease progression, and impaired antitumor immune responses [8–10]. HER2-directed therapies, including trastuzumab or pertuzumab, are well-established in breast, gastric and esophageal cancers, though their success in urothelial carcinoma (UC) setting is limited [11–13]. Recently, a HER2 targeted agent disitamab vedotin (DV) was approved in China for first-line therapy in metastatic and advanced UC, following the results of the RC48-C016 trial [14], while the DESTINY-PanTumor02 trial led to the approval of trastuzumab deruxtecan (T-DXd) in patients with unresectable or metastatic HER2-positive (IHC3 +) solid tumors failed after prior systemic therapy, including metastasized UC [15]. In this review, we aimed to summarize the emerging evidence supporting the efficacy of HER2-targeted regimens in the setting of localized UC including bladder and upper tract UC.
Methods
Protocol and search strategy
The study was prospectively registered at PROSPERO (CRD420250650326) and adhered to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement, including the PRISMA 2020 checklist (Supplementary File 1) and PRISMA for Abstracts checklist (Supplementary File 2) [16]. The inclusion criteria were defined using the Population, Intervention, Comparator, Outcome, and Study Design (PICOS) framework (Supplementary File 3).
We searched MEDLINE (via PubMed), Embase, Web of Science, and Cochrane Central Register of Controlled Trials (CENTRAL) through March 29, 2026. Additionally, the top 200 hits were retrieved using Google Scholar search engine. Chinese databases: SinoMed, Wanfang and China National Knowledge Infrastructure (CNKI) were searched on October 14, 2025. The search was performed using a predefined search strategy which can be found in Supplementary File 4. The deduplication and screening process were performed using Rayyan software (Qatar Computing Research Institute, Doha, Qatar) [17]. Abstract screening, as well as appraisal of full-text articles was performed independently by two authors (Supplementary File 5). All conflicts were resolved through mediation.
Study selection
We included studies testing HER2-targeted regimens as perioperative (neoadjuvant, adjuvant) or organ-sparing treatment in patients with UC reporting on pathological complete response (pCR), clinical complete response (cCR), pathological downstaging (pDS), objective response rate (ORR), bladder preservation rate, and safety of treatment. Both retrospective and prospective studies were eligible. We excluded studies incorporating various solid tumors, which did not separately report outcomes for UC patients.
Data extraction
Data on the sample size, disease setting, HER2 expression, treatment, treatment outcomes (pCR, cCR, pDs, ORR, bladder-preservation rate) and rate of treatment related adverse events (TRAEs) were extracted independently by two authors using a predefined data extraction sheet. For comparative trials, only data for HER2-targeted therapies were extracted. Conflicts were resolved through mediation. Multiple reports of the same trial were treated as a single study; where overlap could not be confirmed or excluded, both reports were retained and examined in sensitivity analyses.
Risk of bias assessment
The risk of bias (RoB) for each study was assessed independently by two authors using the ROBINS-I tool [18]. Conflicts were resolved through mediation.
Statistical analysis
All pooled estimates used all treated patients as the denominator, including patients without surgery or response assessment as non-responders. For pCR and pDS sensitivity analysis included only surgery evaluable patients. Neoadjuvant pCR was stratified by cisplatin eligibility. Further sensitivity analyses excluded potentially overlapping cohorts and were restricted to DV combined with ICI and to full-text publications. Subset analyses based on HER2 expression (denominators reported for each HER2 expression group) and localization of the disease were performed. In bladder-sparing studies, cCR rates were stratified by cCR definition. Random-effects models using inverse-variance Paule-Mandel estimator for τ2 calculation were used to pool log-transformed proportions across studies. Back-transformed outcomes were presented on forest plots with corresponding 95% confidence intervals. A continuity correction of 0.5 was applied to both the numerator and denominator in all studies. Between-study heterogeneity was assessed using Cochran’s Q test and I2. Leave-one-out sensitivity analyses were performed to identify influential studies. Publication bias was evaluated using funnel plots and Egger’s precision-effect test in analyses with >10 studies. Statistical analysis was performed using R software v4.5.1 (R Foundation for Statistical Computing, Vienna, Austria), and the “meta” package.
Results
Included studies
Out of 4701 individual records screened, we identified 33 studies (N = 970) published between 2015 and 2026 that were eligible for systematic review, including eight prospective non-randomized comparative trials (N = 252) [19–26], nine prospective single arm trials (N = 286) [22, 27–34], and 16 retrospective studies (N = 432) [34–48]. Majority of the studies were conducted in China (N = 802) [20–22, 24, 26–39, 41–51] and three were performed in North America (N = 168) [19, 23, 25]. The included studies were relatively small, with a median cohort size of 20 participants (interquartile range [IQR] 15–34), including only two trials with >100 participants [25, 36]. Median age was 67.5 (interquartile range [IQR] 65–69.25). Patients were treated mainly with HER2-targeted ADC–DV alone or combined with toripalimab, tislelizumab, cadonilimab or pembrolizumab. Other drugs included lapatinib, trastuzumab and DN24-02.
Risk of bias analysis
The summary of RoB analysis is presented in Supplementary File 6. According to the ROBINS-I tool, 24 studies were assessed as moderate [20–22, 25–29, 32–35, 37, 39–45, 48, 50–52], eight as serious [19, 23, 24, 36, 38, 46, 47, 53], and one as having critical RoB [30]. The main source of bias domains was outcome measurement as none of the included studies were blinded, outcome measures were partially subjective, and there were missing data. Many included studies were available only as conference abstracts and reported immature data. Additionally, patient selection was an important domain of concern in many cases due to missing robust definitions of inclusion criteria and/or retrospective study design.
Neoadjuvant setting
Bladder cancer
The efficacy of neoadjuvant HER2-targeted therapies was assessed in 15 studies [19, 27–30, 36, 38–41, 41–43, 48, 51, 52] (N = 419). Majority used a combination of DV and ICI (toripalimab/tislelizumab/cadonilimab or pembrolizumab), as summarized in Table 1. Only study by Huang et al. evaluated the efficacy of DV alone [27], and one study combined DV with gemcitabine [52]. Among 13 studies evaluating DV-containing regimens as HER2-targeted therapy, the pooled pCR rate was 48% (95% CI 39–58%, N = 398) with all treated patients in the denominator (Fig. 1), and 54% (95% CI 45–62%, N = 350) among surgery-evaluable patients (Suppl. Figure 1a).
Table 1.
Studies with the HER2-targeted therapies in the neoadjuvant setting
| 1st Author, Year | Study Design (Study Identifier) | Inclusion criteria | Publication type | N of Patients | N of Males | Median Age | Median FU [mo] | Treatment | HER2 expression | pCR [%] | pDS [%] | Additional outcomes | TRAE [%] | TRAE G≥3 [%] | Most common TRAEs | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3+ | 2+ | 1+ | 0 | |||||||||||||||
| MIBC | ||||||||||||||||||
| Huang et al. 2025 [1] | Phase II, SA (ChiCTR2300068270) | treatment-naïve HER2- positive (IHC 2+, 3 +) MIBC (cT2-T4a, N0-1, M0; ECOG PS score 0–1), refuse or unfit for cisplatin-based NAC | Abstract | 17 | 12 | 71 | 10.1 | DV (4 cycles) | 9 | 8 | 41.18 | PaIR = 64.71% | 88.27 | 0 |
Alopecia, AST and ALT elevation, PNP |
|||
| Sheng X. et al. 2025 [2] | Phase II, SA (RC48-C017/ NCT05297552) | treatment-naïve HER2-positive (IHC ≥1) MIBC (cT2-4aN0-1M0) eligible for RC + PLND | Abstract | 47 |
DV + Toripalimab (6 cycles + up to 20 cycles adj. Toripalimab) |
15 | 27 | 5 | 63.6 | 75.8 |
PaIR = 75.8% 1-y EFS = 89.5% |
15.9 | Alopecia, AST, ALT, GGTP increased, PNP | |||||
| Han S. et al. 2025 [3] |
Phase II, SA |
treatment-naïve HER2- positive (IHC 1+, 2+, 3 +) MIBC (T2-T4a, N0-1, M0; ECOG PS score 0–1) | Abstract | 43 | 35 | 65 | 11.3 |
DV + Cadonilimab (6 cycles + 6 (14 Cadonilimab) cycles adj |
31 (2/3 +) | 64.71 | 76.47 | 90.7 |
Fever, rash, bone marrow hypocellular, ALT elevation, immune-mediated myocarditis and pneumonitis |
|||||
| Hu et al. 2025 [4] | Retrospective | treatment-naïve BC, no distant metastases, no UTU; cisplatin ineligible | Article | 102 | 5.5 |
DV + Tislelizumab/ Toripalimab (2–6 cycles) |
74 (2/3 +) | 28 (0/1 +) | 37.3 | 75.5 | 1-y DFS= 97.4% | |||||||
| Li et al. 2025 [5] | Phase II, SA | HER2 positive (HER2 IHC1+, 2+, or 3 +) cT2a-4aN0M0, unfit for cisplatin-based NAC | Abstract | 28 | 68 | 11.8 |
DV + Toripalimab (4 cycles) |
93.75** | ORR = 96.4% | 75 | 14.3 |
Cardiac tachycardia, hepatic dysfunction |
||||||
| Narayan et al. 2016 [6] | Phase I/II | HER2 positive (IHC >1 +), T2-T4, N0, M0, ECOG 0–1 | Article | 6 | 4 | 62.5 |
Lapatinib, +Gem/Cis ( 4 cycles) |
3 (HER2 ≥1 +) | 3 | 17 | 33 | 100 | 100 | Diarrhea, nausea/vomiting, thrombocytopenia | ||||
| Huang H. et al. 2025 [7] | Phase II, SA (NCT05723991) | MIBC (T2-4N0M0) HER2 positive (2/3 +), unfit for cisplatin-based NAC | Article | 26 | 25 | 62 | 16.9 |
DV + Gem/Cis (3/4 cycles) |
6 | 20 | 59 |
ORR = 100% 3 cycles pCR = 31% 4 cycles pCR = 69% |
0 | AST, ALT elevation, decreased appetite, alopecia, PNP | ||||
| Zhang G. et al. 2025 [8] | Retrospective | locally advanced HER2 positive MIBC | Abstract | 20 | 65 | DV + Toripalimab | 80 | 100 |
ORR = 100% mPFS=4.5 mo |
5 | Nausea, alopecia, rash | |||||||
| Zhang et al. 2025 [9] | Retrospective | treatment-naïve HER2-positive MIBC (cT2-4aN0M0) | Article | 17 | 11 | 72.94 (mean) |
DV + Toripalimab/ Tislelizumab (at least 3 cycles) |
7 | 9 | 1 | 0 | 82.35 | 94.12 | ORR = 94.12% | 5.71 | Decreased apetite, asthenia, pruritus, alopecia, leukopenia | ||
| Ge et al. 2025* [10] | Retrospective |
Primary UC confirmed by histopathology; ≥1 DV treatment; Available response assessments; |
Article | 8 |
DV + Tislelizumab/ Tolipalimab (at least 1 cycle) |
8 (2/3 +) | 37.5 | ORR = 100% | Hypoesthesia, elevated ALT, AST | |||||||||
| Guo et al. 2025 [11] | Retrospective (2025R0556) |
localized MIBC (cT2-4aN0-1M0), received ≥4 neoadjuvant therapy with DV + PD-1 inhibitor followed by RC |
Article | 25 | 21 | 69 | 17 |
DV + Tislelizumab/ toripalimab/ pembrolizumab (at least 4 cycles) |
13 | 10 | 1 | 1 | 48 | 88 |
1-yr DFS = 91.5% 1-yr OS = 100% |
92 | 16 | PNP, rash, ALT and AST elevated |
| Hu et al. 2024 [12] | Retrospective | T2-4aN0-2M0 MIBC | Article | 17 | 16 | 65 | DV + Tislelizumab | 13 (2/3 +) | 3 | 1 | 41.2 | 58.8 | 35.3 | ALT and AST elevated, PNP, anemia | ||||
| Wang et al. 2025 [13] | Retrospective | T1-4N0-2M0 UC | Article | 26 | 19 | 66 | DV + ICIs (PD-1) | 22 (2/3 +) no FISH | 4 (0/1 +) | 57.7 | 0 | PNP, rash | ||||||
| Li et al. 2023 [14] | Retrospective | T2-3N0M0 UC | Article | 16 | 15 | 66.12 (mean) | DV + Tislelizumab | 3 | 6 | 6 | 1 | 25 | 62.5 |
ORR = 75% cCR=31.25% |
100 | 31.3 | Rash, hypothyroidism, hyperglycemia | |
| Ruan et al. 2024 [15] | Retrospective | high-risk or very high-risk NMIBC (Tis-T1N0M0), and MIBC (T2-4N0M0) | Article | 21 | 16 | 65 (mean) | 9 | DV + ICIs (PD-1) | 6 | 10 | 5 | 0 | 52.4 | 80.95 | ORR = 85.7% | 100 | 14.3 | Hypertriglyceridemia, hyperglycemia, renal dysfunction |
| UTUC | ||||||||||||||||||
| Bao et al. 2024 [16] | Phase II, SA | locally advanced UTUC eligible to undergo RNU, regardless HER2 expression | Abstract | 14 | 8 | 69 | 65w |
DV + Tislelizumab (4 cycles) |
21.43 | ORR = 78.57% | 7.14 | |||||||
| Chen H. et al. 2025 [17] | Pilot (NCT05837806) | cT1-N0-M0 UTUC HER2 (IHC ≥1 +) | Abstract | 15 | 12 | 71 | 117 d |
DV + Tislelizumab (3 cycles) |
2 | 9 | 3 | 25 | 10.5 | Fatigue, PNP, alopecia | ||||
MIBC muscle-invasive bladder cancer, UTUC upper-tract urothelial carcinoma, N number, FU follow-up, mo month, pCR pathological complete response, pDS pathological down-staging, TRAE treatment-related adverse events, IHC immunohistochemistry, NAC neoadjuvant chemotherapy, RC + PLND radical cystectomy with pelvic lymph node dissection, DV Disitamab vedotin, ICI immune-checkpoint inhibitor, PaIR pathologic muscle-invasive response rate (≤ ypT1N0), EFS event-free survival, DFS disease-free survival, ORR objective response rate, mPFS median progression-free survival, RNU radical nephroureterectomy, AST aspartate aminotransferase, ALT alanine aminotransferase, PNP peripheral sensory neuropathy, GGTP gamma-glutamyl transferase, adj. adjuvant
*part of the bigger trial in the metastatic setting
**measured only among patients with cCR
Fig. 1.

Forest plot of rates of pCR across included neoadjuvant bladder cancer studies using disitamab vedotin a all comers population b cisplatin ineligible
In predominantly cisplatin-eligible all-comers cohort the pooled pCR rate was 51% (95% CI 39–64%, N = 240) [28, 29, 38–43, 48, 51], and 38% in cisplatin-ineligible or cisplatin-declining cohorts (95% CI 29–48%, N = 158) (Fig. 1) [27, 36, 52]. There was no evidence for significant differences between subgroups (p = 0.09) or publication bias (p = 0.19; Suppl. Figure 1b); there was no significant heterogeneity in the cisplatin ineligible/declining cohort (I2 = 22%, p = 0.28), however the heterogeneity was significant in cisplatin-eligible population (I2 = 56%, p = 0.02). Leave-one-out analysis revealed heterogeneity was mainly attributable to Li et al., in which only 8 out of 16 treated patients underwent radical cystectomy (Suppl. Figure 1c) [41]. After excluding Li et al. the pooled pCR rate in all-comers cohort was 54% (45–64%; N = 224), and the heterogeneity was no longer significant (I2 = 39%, p = 0.11) (Supplementary Fig. 1d). In a sub-analysis of 11 studies evaluating only DV combined with ICI the pooled pCR rate was 49% (95% CI 38–61%, N = 354) (Suppl. Figure 2). DV monotherapy and DV combined with gemcitabine were each evaluated in a single study, with pCR in 7/18 (39%) and 13/26 (50%) treated patients, respectively [27, 52]. In additional sub-analysis of studies published as full-text articles the pooled pCR rate was 46% (95% CI 34–59%, N = 270) (Suppl. Figure 3). Excluding potentially overlapping cohorts from the same institutions [28, 40, 41, 43, 51], individually or in combinations, the pooled pCR rate remained stable (range 48–52%; Suppl. Figure 4).
Evidence was insufficient to establish an association between HER2 expression and pCR. The pooled pCR rate was 54% (95% CI 24–81%, N = 20) in HER2 0/1+ tumors and 53% (95% CI 43–63%, N = 134) in HER2 2/3+ tumors, with no evidence for subgroup differences (p = 0.94). The pooled risk ratio (RR) for pCR in patients with HER2 2/3+ expression (N = 52) compared with those with 0/1+ HER2 expression (N = 20) was 0.82 (95% CI 0.52–1.29; p = 0.38) [29, 40, 42] (Supplementary Fig. 5).
pDS was evaluated in eight studies using DV+ICI, with an estimated pooled rate of 74% (95% CI 58–85%, N = 304) (Fig. 2) [28, 29, 36, 38, 39, 42, 43]. There was significant heterogeneity (I2=64%, p<0.01), however leave-one-out analysis revealed that exclusion none of the studies markedly reduce the heterogeneity (Suppl. Figure 6a). Among surgery-evaluable patients pDS rate was 78% (95% CI 69–85%, N = 269) (Suppl. Figure 6b) and there was no significant heterogeneity (I2=30%, p = 0.19), suggesting that heterogeneity in all-treated analysis reflected differences in proportion of patients undergoing sugery. One study was excluded from meta-analysis [30] due to critical RoB, as pCR was assessed only in patients who achieved cCR.
Fig. 2.

Forest plot of rates of pathological down-staging across included neoadjuvant bladder cancer studies
The most common TRAEs among included trials using DV and immunotherapy were alopecia, elevation of liver enzymes, and peripheral sensory neuropathy (PNP). All of them were generally manageable and there was no treatment-related deaths reported. The rate of grade 3 or worse TRAEs varied from 5 to 35%. [27–30, 36, 38–42, 48, 51, 52].
One study evaluated another HER2-directed therapy—lapatinib [19]. After enrolling six patients, the trial was prematurely closed due to a low pCR rate (17%) and the occurrence of serious TRAEs in all participants.
Upper-tract urothelial cancer
Two studies (N = 35) assessed the efficacy of DV with tislelizumab in patients with UTUC [32, 50]. The median age of included participants was 70 years. The estimated pCR rate was 19% (95% CI 9–35%, N = 35) and 23% (95% CI 11–43%, N = 26) among surgery-evaluable patients, without significant heterogeneity between trials (p = 0.69) (Fig. 3; Suppl. Figure 7). The rates of grade 3 or worse TRAEs were low (7.1% and 10.5%) without grade five events.
Fig. 3.

Forest plot of rates of pCR across included neoadjuvant UTUC studies
Organ-sparing setting
Bladder-sparing
Six trials (N = 146) [22, 31, 35, 37, 44, 45] evaluated a bladder-sparing strategy using DV and ICI following primary TURB. As cCR definitions varied substantially between studies (Table 2), results were stratified by response definition. In studies requiring complete absence of residual tumor [35, 44, 45], the pooled cCR rate was 65% (95% CI 44–82%, N = 38); in studies that allowed for residual non-muscle-invasive disease (≤ Ta/Tis) it was 54% (95% CI 41–67%, N = 61) [22, 31], and in one study without a reported definition, cCR was achieved in 29/47 (62%) patients (Fig. 4a) [37]. There was no significant difference between definition groups (p = 0.6).
Table 2.
Studies with the HER2-targeted therapies in the organ-sparing setting
| 1st Author, Year | Study Design (Study Identifier) | Inclusion criteria | Publication type | cCR definition | N of Patients | N of Males | Median Age | Median FU | Treatment | HER2 expression | cCR [%] | Organ preserv [%] | Additional outcomes | TRAE [%] | TRAE G≥3 [%] | Most common TRAEs | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3+ | 2+ | 1+ | 0 | ||||||||||||||||
| Bladder-sparing | |||||||||||||||||||
| Huang et al. 2024 [18] | Phase II (PUNCH02, ChiCTR2400080073) | HER2 (2+/3 +) cT2-4aN0M0 | Abstract | normal urine cytology and MRI imaging, bladder biopsies ≤cTa | 10 | 7 | 66.6 | 5.7 |
DV + Tislelizumab (4 cycles) |
7 | 3 | 70 | 80 | 0 | PNP, rash, alopecia | ||||
| Wang A. et al. 2024 [19] | Retrospective | MIBC (T2N0M0-T4N2M0) | Article | radiologcial (RECIST 1.1) and cystoscopy visual assessment | 11 | 5 | 67 | 19 |
DV+ (Toripalimab/ Tislelizumab) (at least 2 cycles) |
3 | 5 | 3 | 54.5 | 72.7 at 16 mo | ORR = 81.8% | 100 | 27.3 | Decreased appetite, fatigue, rash, PNP, anemia, nausea | |
| Wei et al. 2023 [20] | Retrospective | MIBC cT2-T4aN0-2M0 | Article | MRI assessment (RECIST 1.1) with bladder biopsy/TURB-T | 9 | 8 | 72 | 12 |
DV + Toripalimab/ Tislelizumab (at least 2 cycles) |
4 | 3 | 1 | 1 | 55.6 |
ORR = 88.9% median rPFS = 12 mo |
88.9 | 22.2 | Decreased appetite, fatigue, rash | |
| Cao et al. 2025 | Retrospective | Previously untreted MIBC (cT2-T3N0-1M0) with HER2 expression of IHC ≥ 2+ | Abstract | no residual tumor in re-TURBT, no tumor on imaging, negative urine cytology | 18 |
DV + Toripalimab (6 cycles) |
3 | 15 | 83.3 | 83.3 | ORR = 94.4% | ||||||||
| Ou et al. 2024 [21] | Retrospective | MIBC (T2-4N0-1M0) HER2 (≥ 1 +) | Abstract | - | 47 | 40 | 66 | 8 |
DV + Toripalimab |
8 | 23 | 16 | 61.7 | 63.8 |
pDS=78.7% 1-yr BI-DFS=100% |
25 | Anemia, elevated ALT, fatigue | ||
| Wen et al. 2025 [22] | Phase Ib/II, SA (HOPE−03, ChiCTR2200060153) | MIBC (cT2-4bN0-3M0-1a) HER2 (≥ 1 +) | Article | cT0/Ta/Tis: no detectable tumour on chest/abdominal CT, bladder MRI and cystoscopy | 51 | 44 | 70 | 12.8 |
DV + Tislelizumab |
22 | 26 | 3 | 56.5 | 70.6 | ORR = 86.95% | 33.3** | PNP, erythema, elevated ALT and AST | ||
| Bladder-sparing (TMT) | |||||||||||||||||||
| Chen Y. et al. 2025 [23] | Retrospective | MIBC ineligible or refused radical cystectomy (RC) and received TURBT and synchrotron radiation (50–70 Gy) and/or RNU | Abstract | - | 42*** | 38.1 | RT + DV | 42* only as positive | Relapse rate 35.7% | 66.7 | 28.6 | Elevated ALT and AST, pruritus, fatigue | |||||||
| Dahl et al. 2024 [24] | Phase I/II, non-randomized (NCT00238420) | Locally advanced MIBC, HER2 positive (IHC 2/3 +) | Article | Negative cystocsopy/umor biopsyv | 20 | 18 | 79.5 | 2.3 yr | RT + paclitaxel + trastuzumab | 20 (2/3 +) | 72.2 |
2-yr OS=64.97% 3-yr OS = 56.15% 1-yr DFS = 63.95% 3-yr DFS = 25% |
80 | ||||||
| Zhang L et al. 2025 [25] | Phase II (NCT05979740) | HER2 (IHC 2/3 +) T2-T4aN0M0 | Article | Negative imaging, cystoscopy with biopsies, and urine cytology | 6 | 5 | 69.5 | 12.3 |
RT + DV + Toripalimab (up to 12 cycles) |
6 (2/3 +) | 83.3 | 100 | 33.3 | PNP, elevated ALT and AST, hyperlipidemia, rash, fatigue | |||||
| Kidney-sparing | |||||||||||||||||||
| Ye et al. 2025 [26] | Phase II (WUTSUP-03) |
localized UTUC patients (cT≤2N0M0) characterized by conditions such as solitary kidney, bilateral tumors, impending/already renal insufficiency and individual refusal/ineligibility for RNU |
Abstract | - | 34 | 18 |
DV + ICI (3–4 cycles) |
3 | 24 | 7 | 73.53 | 91.18% |
1-yr DFS = 67.65% 1-yr CFS = 91.18% |
0 | |||||
| Huang et al. 2025 [27]15–10-2026 12:56:00 | Phase II (DISTINCT-I, NCT05912816) | Abstract | - | 19 | 13 |
DV + Tislelizumab (2–4 cycles) |
6 | 2 | 7 | 4 | 73.7 | 1-yr KI-EFS = 68.4% | 0 | ||||||
MIBC muscle-invasive bladder cancer, UTUC upper-tract urothelial carcinoma, N number, FU follow-up, mo month, cCR clinical complete response, TRAE treatment-related adverse events, IHC immunohistochemistry, RC + PLND radical cystectomy with pelvic lymph node dissection, RNU radical nephroureterectomy, RT radiotherapy, DV Disitamab vedotin, ICI immune-checkpoint inhibitor, ORR objective response rate, rPFS radiological progression-free survival, pDS pathological down-staging, BI-DFS bladder intact disease-free survival, CFS conversion-free survival, KI-EFS kidney-intact event-free survival, PNP peripheral sensory neuropathy
**7 patients experienced immune relates AEs, 10 patients experienced DV related AEs
***not stated how many UTUC patients
v—defined as complete response
Fig. 4.

Forest plot of rates of a cCR and b bladder preservation among included bladder-sparing trials
The pooled bladder preservation rate was 70% (95% CI 61–77%, N = 137), with no evidence for significant heterogeneity (p = 0.66) (Fig. 4b). The most common TRAEs were PNP, alopecia and fatigue. In trial by Huang et al. there was no grade 3 or worse TRAE, in other trials it varied from 22 to 27%. No grade five events were reported [22, 37, 44, 45].
Additionally, three trials (N = 68) [23, 26, 34] assessed the role of trimodal therapy (TMT) in bladder-sparing setting with the use of HER2-targeted agents. Trial by Chen Y. et al. (N = 42) assessed efficacy of DV combined with radiotherapy [34], trial by Dahl et al. (N = 20) the combined treatment with paclitaxel and trastuzumab [23], and trial by Zhang L. et al. (N = 6) DV with toripalimab [26]. Because response definitions differed (cystoscopy and/or biopsy in Dahl et al.; imaging, cystoscopy with biopsy and cytology in Zhang L. et al.), results were not pooled: complete response was achieved in 13/20 (65%) and 5/6 (83%) patients, respectively. Importantly in trial by Dahl et al. the rate of grade ≥3 TRAEs was 80%, while in two trials using DV it was around 30% (predominantly PNP and elevated liver enzymes) [26, 34].
Kidney-sparing
HER2-targeted therapy has been also evaluated as a kidney-sparing strategy in patients with UTUC with DV+ICI. In WUTSUP-03, 1-year disease-free survival was 67.65% and 91.18% of patients maintained their kidneys during the first year after treatment [20]. In DISTINCT-I, kidney preservation at 1-year was 68.4% [21]. Neither study reported criteria for cCR; cCR was achieved in 25/34 (74%) and 14/20 (70%) patients, respectively. None of the studies reported TRAEs of grade 3 or worse.
Adjuvant setting
Bladder cancer
Two trials assessed the efficacy of HER2-targeted agents as adjuvant treatment in patients with MIBC [25, 46] (Table 3). NeuACT trial assessed the role of DN24-02 autologous cellular immunotherapy in comparison with standard of care (SOC) surveillance in 142 patients with high-risk MIBC. There was no significant difference in OS (HR 0.96; p =0.87) or recurrence-free survival (RFS) (HR 0.99; p = 0.97), and the trial was prematurely terminated for futility [25].
Table 3.
Studies with the HER2-targeted therapies in the adjuvant setting
| 1st Author, Year | Study Design (Study Identifier) | Inclusion criteria | Publication type | N of Patients | N of Males | Median Age | Median FU | Treatment Drug | HER2 expression | Additional outcomes | TRAE [%] | TRAE G≥3 [%] | Most common TRAEs | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3+ | 2+ | 1+ | 0 | |||||||||||||
| MIBC | ||||||||||||||||
| Bajorin et al. 2016 [27] | Phase II, randomized (NeuACT, NCT01353222) | High-risk MIBC post-RC HER2 positive (IHC ≥1) | Abstract |
142 (both arms) |
13.2 |
DN24-02 (3 infusions) |
Median OS = 37 mo Median DRFS = 11.9 mo |
|||||||||
| Xu et al. 2023 [28] | Retrospective |
The tumors in these patients were confined to the bladder or ureter. Surgical treatment options included TURB, RC, RNU; depending on the tumor location and size HER-2 positivite (IHC ≥1) |
Article | 32 | 21 | 69.2 (mean) |
DV (3 months) |
5 | 16 | 11 | 0 | Recurrence rate = 9.4% | 21.9 | 12.5 | Anemia, PNP, nausea, decreased appetite | |
| UTUC | ||||||||||||||||
| Liu S. et al. 2025 [29] | Phase II, SA (NCT05917158) | histologically confirmed HER2 IHC 2+/3+ UTUC after radical surgery and were staged as T2-4NanyM0 or TanyN1-2M0, with no prior neoadjuvant therapy | Abstract | 45 | 35 | 68 | 12.2 |
DV + Toripalimab (6 cycles + toripalimab up to 1 year) |
9 | 36 | 1-y DFS=90% | 100 | 20 | Nausea, pruritus, rash, hypothyroidism | ||
| Tao et al. 2025 [30] | Phase II, open label, non-randomized (NCT06210490) |
cisplatin-intolerant pts with HER2- overexpressing (Immunohistochemistry, IHC 2+, 3 +) UTUC after RNU staged as pT2N0M0 with high-grade/multifocal disease/positive surgical margin, pT3-4 N0 M0 or pTany N1-2 M0 |
Abstract | 15 | 6 |
DV + RT (DV for 6 months) |
6-mo DFS = 100% | 6.7 | Abdominal pain, rash, leukopenia, elevated Alt and AST | |||||||
| Wang et al. 2025 [31] | Retrospective | Locally advanced HER2 positive (IHC 2/3 +).UTUC post RNU | Abstract | 21 | 13 | 68 | 15 |
DV + PD-1 inhibitor (at least 5 cycles + PD-1 inhibitor up to 1 year) |
15 | 6 | 15-mo DFS = 76.2% | 42.9 | ||||
MIBC muscle-invasive bladder cancer, UTUC upper-tract urothelial carcinoma, N number, FU follow-up, mo month, cCR clinical complete response, TRAE treatment-related adverse events, IHC immunohistochemistry, TURB transurethral resection of bladder tumor, RC radical cystectomy, RNU radical nephroureterectomy, DV Disitamab vedotin, ICI immune-checkpoint inhibitor, RT radiotherapy, OS overall survival, DRFS disease -free survival
The second trial by Xu et al. assessed the role of adjuvant DV in patients with tumors confined to bladder or ureter after definitive treatment, in the cohort of 32 patients the recurrence rate in DV group was significantly lower compared to chemotherapy group (9.4% vs. 20.2%, p = 0.007). The rate of adverse events was also lower in the DV group (12.5% vs. 20.2%, p = 0.022) [46].
Upper-tract urothelial cancer
The role of adjuvant therapy in UTUC was evaluated in three trials testing DV [24, 33, 47] (Table 3). In the first study by Liu S. et al. in patients after radical surgery without neoadjuvant therapy DV was combined with toripalimab, resulting in 1-year disease-free survival (DFS) of 90%, with 20% of patients experiencing serious TRAEs [33]. In the second trial by Tao et al. [24] in patients who were cisplatin-unfit and high-risk after nephroureterectomy DV was combined with radiotherapy, with no recurrences within six months after treatment and 6.7% rate of serious TRAEs. Finally, in the study by Wang et al. [47] in patients after nephroureterectomy DV was combined with PD-1 inhibitor, achieving 15-month DFS of 76.2% with 42.9% of patients experiencing TRAEs.
Discussion
In this systematic review and meta-analysis, HER2-directed regimens, predominantly DV-containing combinations, showed promising activity across perioperative strategies in patients with UC. In the neoadjuvant setting in BC, the pooled pCR rate was 48%, with pDS reaching 74%. Evidence was insufficient to establish an association between HER2 expression and response. In organ-preserving cohorts, reported responses were encouraging for both bladder- and kidney-sparing regimens; however, follow-up periods were short and reported outcomes, especially cCR varied in their definitions. In the adjuvant setting, outcomes were heterogeneous and the available data did not permit formal meta-analysis. DN24-02 failed to improve survival; yet the emerging data on DV seem promising, and larger cohorts with longer follow-up are needed for definitive conclusions.
While majority of the included studies were available only as conference abstracts and DV was combined with various ICIs, eligibility criteria and analysis populations differed across studies. Importantly, pooled estimates reflect DV-containing regimens and do not isolate effect of HER2 targeting. In the neoadjuvant setting, patients with treatment-naïve, locally-advanced disease were included. Similarly, in organ-sparing cohorts, disease was predominantly locally advanced, apart from two trials including patients ineligible or who refused operation [20, 34].
In the neoadjuvant setting, the pooled pCR rate of 48% achieved with DV-containing regimens is promising and worth testing in randomized trials, as those results are comparable with response achieved in previous trials with single agent ICIs (ABACUS, NABUCCO or PURE-01) [54–56], where the pCR rates ranged from 31 to 46%. When compared with other ADCs, combination EV and pembrolizumab in KEYNOTE−905 achieved pCR of 57% in the cisplatin-ineligible patients, while in our analysis pCR in the cisplatin-unfit cohort it was 38% [57]. In trial KEYNOTE-B15 in cisplatin-eligible population a pCR rate was 55.8% [58]. Yet, these results should be interpreted cautiously as only three studies assessed defined cisplatin-ineligible cohort [27, 36, 52]. Other included trials did not specify if they included cisplatin-unfit patients.
Our analysis showed that currently there is insufficient evidence to establish association between HER2 expression and response. It should not be interpreted as evidence that HER2 expression does not influence response, but there is evidence showing HER2-directed ADCs remain active in tumors with low HER2 expression in breast cancer [59]. It could potentially be explained by the pharmacology of ADCs—as the, payload release and bystander effect may reduce dependence on high target expression, but sample size was too small to draw definitive conclusions [60, 61]. Importantly, majority of included studies used standard immunohistochemistry (IHC), there is no centralized protocol for HER2-expression assessment in UC [62]. Staining was highly center-dependent with various antibodies, cut-off values, scoring systems and source of tissue across studies. In addition, only a minority of studies reported outcomes stratified by HER2 expression, limiting statistical power.
A further constraint is that evidence comprises mainly of surrogate endpoint, with most studies reporting pCR (neoadjuvant) and cCR (organ-sparing) and mature survival data are limited. Although pCR has been proven to be an early efficacy signal [63], cCR is not a reliable outcome, confirmative for true disease eradication [64]. Also its definition varied across studies (Table 2) some studies required complete absence of residual tumor, whereas others permitted residual non-muscle-invasive disease; for example in PUNCH02, cCR was defined as normal urine cytology and MRI imaging with bladder biopsies ≤cTa [22], and only in trials by Cao et al., Dahl et al. and Zhang et al. it was confirmed by biopsy [23, 26, 35]. While some of the included studies were supported with the liquid-biopsies analyses, this approach needs further validation in the prospective randomized trials. Moreover, the short follow-up in most organ-sparing studies is insufficient to mitigate the risk serious AEs associated with the treatment.
Primary limitations of this study include the predominance of single-arm trials with small sample sizes, many of which were published as conference abstracts, and Chinese databases were searched through October 14, 2025. Second, there were substantial differences in the number of treatment cycles across included trials. Third, in several studies, BC and UTUC were analyzed together, which precludes the exact characteristic of HER2 expression and treatment response within each cohort. Fourth, majority of these studies were conducted in China and used DV, currently not approved outside China, which was often combined with ICIs such as tislelizumab and toripalimab which are also not available outside China. It limits the generalizability of the findings and further validation in western population is needed. The difficulties in introducing anti-HER2 therapies in the world-wide practice are also underscored by other authors and remain one of the biggest challenge in current uro-oncology practice [65]. So far there is only few ongoing international trial assessing efficacy of DV in UC (NCT04879329 and NCT05911295) [66, 67]. Additionally, proportion of treated patients undergoing surgery varied across studies; partial overlap between cohorts from the same centers could not be excluded. Finally, as ROBINS-I was developed for comparative non-randomized studies, its application to single-arm data required adaptation, and bias due to confounding could not be assessed.
Conclusion
Neoadjuvant DV-containing regimens show promising activity in patients with bladder cancer. Current evidence is insufficient to establish an association between HER2 expression and response. Emerging data indicate a possible role in the bladder-sparing setting with low rates of toxicity and no G5 safety signals. However, current evidence is based on single-arm studies with surrogate endpoints, limited follow-up and heterogeneous cCR definitions. Prospective, comparative trials with standardized HER2 assessment, survival follow-up and global validation, preferably already integrating molecular response biomarker, are needed to comprehensively define role of HER2-targeted ADCs in perioperative UC setting.
Supplementary Information
Below is the link to the electronic supplementary material.
Author contributions
A.S. and M.M. wrote the main manuscript; A.S. prepared all the figures; A.S., D.B., W.D., X.Z., conducted data extraction and risk of bias analysis; A.S. and D.B. performed search; A.S. performed statistical analysis; A.S., M.M. E.L., S.F.S conceptualization of the study; E.K., B.E., P.R., P.K., B.S. E.C, J.R., P.Z., S.F.S critically read and reviewed the article.
Funding
Open access funding provided by Medical University of Vienna. No funding was received for conducting this study.
Data availability
All data analyzed during this study are derived from previously published studies, which are cited in the manuscript. The extracted data supporting the findings of this meta-analysis are available within the article and its supplementary information files.
Declarations
Conflict of interest
Shahrokh F. Shariat reports receiving honoraria from Astellas, AstraZeneca, BMS, Ferring, Ipsen, Janssen, MSD, Olympus, Pfizer, Roche, and Takeda; having a consulting or advisory role in Astellas, AstraZeneca, BMS, Ferring, Ipsen, Janssen, MSD, Olympus, Pfizer, Pierre Fabre, Roche, and Takeda; and being in the speakers’ bureau of Astellas, Astra Zeneca, Bayer, BMS, Ferring, Ipsen, Janssen, MSD, Olympus, Pfizer, Richard Wolf, Roche, and Takeda. The remaining authors have nothing to disclose.
Ethical approval
Not applicable.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Agata Suleja and Wen Dong have contributed equally to this work.
Contributor Information
Pixiao Zhou, Email: zpx2019969@163.com.
Shahrokh F. Shariat, Email: shahrokh.shariat@meduniwien.ac.at
References
- 1.Rintala E, Hannisdahl E, Fosså SD, Hellsten S, Sander S (1993) Neoadjuvant chemotherapy in bladder cancer: a randomized study. Nordic Cystectomy Trial I. Scand J Urol Nephrol 27(3):355–362. 10.3109/00365599309180447 [DOI] [PubMed] [Google Scholar]
- 2.Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349(9):859–866. 10.1056/NEJMoa022148 [DOI] [PubMed] [Google Scholar]
- 3.Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y et al (2021) Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med 384(22):2102–2114. 10.1056/NEJMoa2034442 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Apolo AB, Ballman KV, Sonpavde G, Berg S, Kim WY, Parikh R et al (2025) Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma. N Engl J Med 392(1):45–55. 10.1056/NEJMoa2401726 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Matsukawa A, Cormio A, Miszczyk M, Parizi MK, Fazekas T, Tsuboi I et al (2025) Impact of immune checkpoint inhibitors as neoadjuvant therapy for muscle-invasive bladder cancer: a systematic review, meta-analysis, and network meta-analysis. Eur Urol Oncol 8(6):1673–1684. 10.1016/j.euo.2025.02.009 [DOI] [PubMed] [Google Scholar]
- 6.Vulsteke C, Adra N, Danchaivijitr P, Sabadash M, Rodriguez-Vida A, Zhang Z et al (2026) Perioperative Enfortumab Vedotin and Pembrolizumab in bladder cancer. N Engl J Med.2026 Apr 2;394(13):1257–69. 10.1056/NEJMoa2511674 [DOI] [PubMed] [Google Scholar]
- 7.Galsky MD, Valderrama BP, Maruzzo M, Font Pous A, Ciuleanu TE, Chatzkel JA et al (2026) Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: randomized, open-label, phase 3 KEYNOTE-B15 study. J Clin Oncol 44(7_suppl):LBA630–LBA630. 10.1200/JCO.2026.44.7_suppl.LBA630 [DOI] [Google Scholar]
- 8.Iqbal N, Iqbal N (2014) Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int 2014:1–9. 10.1155/2014/852748 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Wu S, Zhang Q, Zhang F, Meng F, Liu S, Zhou R et al (2019) HER2 recruits AKT1 to disrupt STING signalling and suppress antiviral defence and antitumour immunity. Nat Cell Biol 21(8):1027–1040. 10.1038/s41556-019-0352-z [DOI] [PubMed] [Google Scholar]
- 10.Moasser MM (2007) The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26(45):6469–6487. 10.1038/sj.onc.1210477 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Kim M, Lee JL, Shin SJ, Bae WK, Lee HJ, Byun JH et al (2023) Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18. ESMO Open 8(4):101588. 10.1016/j.esmoop.2023.101588 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Hussain MHA, MacVicar GR, Petrylak DP, Dunn RL, Vaishampayan U, Lara PN et al (2007) Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/ neu –positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 25(16):2218–2224. 10.1200/JCO.2006.08.0994 [DOI] [PubMed] [Google Scholar]
- 13.Bryce AH, Kurzrock R, Meric-Bernstam F, Hurwitz H, Hainsworth JD, Spigel DR et al (2017) Pertuzumab plus trastuzumab for HER2-positive metastatic urothelial cancer (mUC): preliminary data from MyPathway. J Clin Oncol 35(6_suppl):348–348. 10.1200/JCO.2017.35.6_suppl.348 [DOI] [Google Scholar]
- 14.Sheng X, Zeng G, Zhang C, Zhang Q, Bian J, Niu H et al (2025) Disitamab vedotin plus toripalimab in HER2-expressing advanced urothelial cancer. N Engl J Med 393(23):2324–2337. 10.1056/NEJMoa2511648 [DOI] [PubMed] [Google Scholar]
- 15.Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, González-Martín A et al (2024) Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol 42(1):47–58. 10.1200/JCO.23.02005 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 10.1136/bmj.n71 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan—a web and mobile app for systematic reviews. Syst Rev 5(1):210. 10.1186/s13643-016-0384-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 10.1136/bmj.i4919 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Narayan V, Mamtani R, Keefe S, Guzzo T, Malkowicz SB, Vaughn DJ (2016) Cisplatin, gemcitabine, and lapatinib as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer Res Treat 48(3):1084–1091. 10.4143/crt.2015.405 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Ye J, Chen Z, Tu X, Liao X, Zheng L, Wang Q et al (2025) A0059—kidney-sparing approach for selected localized high-risk upper tract urothelial carcinoma: a pilot study combining endoscopic Thulium laser ablation with perioperative Disitamab vedotinand immune checkpoint inhibitors. Eur Urol 87:S854. 10.1016/j.eururo.2025.09.3266 [DOI] [Google Scholar]
- 21.Huang J, Xia L, Chen Q, Ng C, Hu H, Xue W (2025) 3071MO Disitamab vedotin plus tislelizumab as nephron-sparing therapy for high-risk upper tract urothelial carcinoma: the phase II DISTINCT-I trial. Ann Oncol 36:S1590. 10.1016/j.annonc.2025.08.3685 [DOI] [Google Scholar]
- 22.Huang B, Wang Z, Luo C, Wu Y, Lei J, Chen L et al (2024) PUNCH02: primary results from a phase II study of tislelizumab combined with disitamab vedotin as a bladder preservation therapy for urine tumor DNA (utDNA)-defined clinical complete response (cCR) MIBC patients. Ann Oncol 35:S1159–S1160. 10.1016/j.annonc.2024.08.2095 [DOI] [Google Scholar]
- 23.Dahl DM, Karrison TG, Michaelson MD, Pham HT, Wu CL, Swanson GP et al (2024) Long-term outcomes of chemoradiation for muscle-invasive bladder cancer in noncystectomy candidates. Final results of NRG Oncology RTOG 0524—a phase 1/2 trial of paclitaxel + trastuzumab with daily radiation or paclitaxel alone with daily irradiation. Eur Urol Oncol 7(1):83–90. 10.1016/j.euo.2023.05.013 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Tao Z, Guo X, Xu C, Li X, Tang Q, Li X. Preliminary results of a phase II study to evaluate the efficacy and safety of disitamab vedotin (RC48-ADC) in combination with radiotherapy for adjuvant therapy in upper tract urothelial carcinoma. J Clin Oncol. 2025 Jun 1;43(16_suppl):e16583–e16583. doi:10.1200/JCO.2025.43.16_suppl.e16583
- 25.Bajorin DF, Sharma P, Quinn DI, Plimack ER, Hoffman-Censits JH, O’Donnell PH et al (2016) Phase 2 trial results of DN24–02, a HER2-targeted autologous cellular immunotherapy in HER2+ urothelial cancer patients (pts). J Clin Oncol. 34(15_suppl):4513–4513. 10.1200/JCO.2016.34.15_suppl.4513 [DOI] [Google Scholar]
- 26.Zhang L, Jin D, Zang J, Qian L, Zhang T, Wu Y et al (2025) Disitamab vedotin combined with toripalimab and radiotherapy for multimodal organ-sparing treatment of muscle invasive bladder cancer: a proof-of-concept study. Neoplasia 68:101216. 10.1016/j.neo.2025.101216 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Huang H, Zhang X, Xie Y, Zhao Y, Zhang Y, Fan X. Neoadjuvant treatment with disitamab vedotin monotherapy in patients with HER2-overexpressing muscle invasive bladder cancer (MIBC): an open-label, single-arm, phase II study., J Clin Oncol. 2025 Jun 1;43(16_suppl):e16584–e16584. 10.1200/JCO.2025.43.16_suppl.e16584 [DOI]
- 28.Sheng X, Zhang C, Ji Y, Zhou L, Zou B, Huang H et al (2025) Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression: updated efficacy and safety results from the phase II RC48-C017 trial. J Clin Oncol 43(5_suppl):665–665. 10.1200/JCO.2025.43.5_suppl.665 [DOI] [Google Scholar]
- 29.Han S, Yang F, Zhang Y, Ye X, Shi H, Jia B, et al. Updated results from a phase II study of perioperative disitamab vedotin (RC48-ADC) plus cadonilimab (AK104) for HER2-expressing muscle-invasive bladder cancer (MIBC). J Clin Oncol. 2025 Jun 1;43(16_suppl):4588–4588. doi:10.1200/JCO.2025.43.16_suppl.4588
- 30.Li C, Zhu J, Cheng F, Yu W, Chen Z, Song C et al (2025) Effectiveness and safety of RC48-ADC in combination with toripalimab as neoadjuvant treatment in HER2-positive muscular invasive urothelial bladder cancer patients. J Clin Oncol 43(5_suppl):710–710. 10.1200/JCO.2025.43.5_suppl.710 [DOI] [Google Scholar]
- 31.Wen F, Lin T, Zhang P, Shen Y (2024) RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03). Front Oncol 13:1233196. 10.3389/fonc.2023.1233196 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Bao Y, Liao X, Wei Q (2024) Neoadjuvant disitamab vedotin combined with tislelizumab for locally advanced upper urinary tract carcinoma: a pilot study for a phase II trial. Eur Urol 85:S804. 10.1016/S0302-2838(24)00674-2 [DOI] [Google Scholar]
- 33.Liu S, Miao H, Xue S, Xu F, Xu Z, Fu D, et al. Efficacy and safety of disitamab vedotin (RC48) combined with toripalimab as adjuvant therapy after radical surgery for patients with HER2-overexpression upper tract urothelial cancer (UTUC): a single-arm, prospective, phase 2 clinical trial. J Clin Oncol. 2025 Jun 1;43(16_suppl):4590–4590. 10.1200/JCO.2025.43.16_suppl.4590 [DOI]
- 34.Chen Y, Luo F, Li J. Long-term efficacy and safety of disitamab vedotin monotherapy versus chemotherapy in bladder-preserving treatment of Chinese real-world patients with muscle-invasive urothelial cancer: a retrospective real-world study. J Clin Oncol. 2025 Jun 1;43(16_suppl):e16578–e16578. 10.1200/JCO.2025.43.16_suppl.e16578 [DOI]
- 35.Cao Y, Li R, Wang S, Ma J, Ji Y, Lin C et al (2025) Changes in circulating tumor cells (CTCs) and HER2 expression in evaluating the efficacy of neoadjuvant disitamab vedotin plus toripalimab treatment in patients with muscle-invasive bladder cancer (MIBC). J Clin Oncol 43(5_suppl):837–837. 10.1200/JCO.2025.43.5_suppl.837 [DOI] [Google Scholar]
- 36.Hu J, Yan L, Liu J, Chen M, Liu P, Deng D et al (2025) Efficacy and biomarker analysis of neoadjuvant disitamab vedotin (RC48‐ADC) combined immunotherapy in patients with muscle‐invasive bladder cancer: a multi‐center real‐world study. iMeta 4(3):e70033. 10.1002/imt2.70033 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Ou Z, Hu J, Chen M, Li Y, Zu X (2024) Efficacy and safety of neoadjuvant therapy with disitamab vedotin plus toripalimab in treating muscle invasive urothelial bladder cancer followed by selective bladder-preserving or radical cystectomy. J Clin Oncol 42(16_suppl):e16590–e16590. 10.1200/JCO.2024.42.16_suppl.e16590 [DOI] [Google Scholar]
- 38.Zhang G, Fu Q, Zhang F, Yang F, Hou H (2025) Efficacy and safety of disitamab vedotin combined with toripalimab as neoadjuvant treatment for patients with locally advanced muscle-invasive bladder cancer: a mono-institutional retrospective study. J Clin Oncol 43(5_suppl):726–726. 10.1200/JCO.2025.43.5_suppl.726 [DOI] [Google Scholar]
- 39.Zhang C, Yu Y, Zhou Q, Ouyang J, Zhang Z (2025) Disitamab vedotin vs. gemcitabine-cisplatin regimen with immunotherapy: a comparative analysis of efficacy and safety in muscle-invasive bladder cancer. Front Immunol 16:1549647. 10.3389/fimmu.2025.1549647 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Hu X, Mei Y, Li L, Gou X (2024) Efficacy and safety of ADC combined with PD-1 inhibitors versus GC regimen in neoadjuvant therapy for bladder cancer. J Chongqing Med Univ 49(6). 10.13406/j.cnki.cyxh.003515 [DOI]
- 41.Li S, Li X, Chen Y, Wang M, He W, Kuang Y, et al. (2023) Efficacy and safety of disitamab vedotin combined with tislelizumab in the neoadjuvant treatment of bladder cancer. Chin J Urol. 10.3760/cma.j.cnl12330-20230616-00217 [DOI]
- 42.Ruan Z, Lin Y, Ke Z, Fang S, Chen S, Chen Y et al (2024) Efficacy and safety of Disitamab Vedotin compared with GC regimen combined with immunotherapy in the bladder-preserving treatment of bladder cancer. J Clin Urol. 39(11):1000–7. 10.13201/j.issn.1001-1420.2024.11.012 [DOI] [Google Scholar]
- 43.Guo X, Wang S, Ma Y, Du Y, Chen Y, Wang Q et al (2025) Disitamab vedotin (RC48-ADC) combined with immunotherapy as neoadjuvant therapy for localized muscle-invasive bladder cancer: a multicenter real-world study. NPJ Precis Oncol. 10.1038/s41698-025-01211-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Wang A, Chen M, Li D, Shi J, Tang W, Zhang Z et al (2024) Disitamab vedotin alone or in combination with immune checkpoint inhibitors in bladder-sparing treatment of muscle-invasive bladder cancer: a real-world study. Clin Genitourin Cancer 22(3):102085. 10.1016/j.clgc.2024.102085 [DOI] [PubMed] [Google Scholar]
- 45.Wei Y, Zhang R, Yu C, Hong Z, Lin L, Li T et al (2023) Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center’s real-world study. Front Pharmacol 14:1230395. 10.3389/fphar.2023.1230395 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Xu Q, Jiang Y, Wan S, He Y (2023) Comparison of the clinical efficacy of Disitamab Vedotin and postoperative chemotherapy in the treatment of HER-2 positive locally advanced urothelial carcinoma. J Chongqing Med Univ. 48(8):1000–4. 10.13406/j.cnki.cyxb.003298 [DOI] [Google Scholar]
- 47.Wang X, et al. A0072 – Effectiveness of adjuvant disitamab vedotin combined with PD-1 inhibitor for high recurrence risk patients with upper tract urothelial carcinoma: A preliminary study. Eur Urol. 2025 Mar;87(Suppl 1):S871. 10.1016/S0302-2838(25)00085-5 [DOI]
- 48.Ge H, Liu C, Shen C, Hu D, Zhao X, Wang Y et al (2025) The effectiveness and safety of RC48 alone or in combination with PD-1 inhibitors for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study. J Transl Med 23(1):243. 10.1186/s12967-025-06237-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Yang C, Huang H, Zeng X, Dai H, Zhou G, Wang S et al (2024) Efficacy and safety of disitamab vedotin combined with gemcitabine as neoadjuvant therapy for muscle-invasive bladder cancer: a multi-center, single-arm, phase II trial. Ann Oncol 35:S1148. 10.1016/j.annonc.2024.08.2069 [DOI] [PubMed] [Google Scholar]
- 50.Chen H, Hu H, Shen C, Qie Y, Wu Z, Bai Y, et al. Neoadjuvant tislelizumab combined with disitamab vedotin (RC48) for patients with Her-2 expressing upper tract urothelial carcinoma: a pilot study. J Clin Oncol. 2025 Jun 1;43(16_suppl):e16588–e16588. doi:10.1200/JCO.2025.43.16_suppl.e16588
- 51.Wang Y, Yi X, Yang L, Yu W, Hao H. The effect and treatment-related adverse events of disitamab vedotin combined with programmed death-1 inhibitor in the treatment of urothelial carcinoma. J Mod Urol. 2025. Published online 2025 Oct 10. https://link.cnki.net/urlid/61.1374.R.20251009.1330.024
- 52.Huang H, Ma W, Zeng X, Liu B, Dai H, Zhou G et al (2025) Efficacy and safety of disitamab vedotin combined with gemcitabine as neoadjuvant therapy in muscle-invasive bladder cancer: an open-label, multicenter, single-arm, phase 2 trial. Eur Urol. 10.1016/j.eururo.2025.10.009 [DOI] [PubMed] [Google Scholar]
- 53.Wen F, Lin T, Tan P, Deng J, Ren M, Zhang M et al (2025) A multi-center phase Ib/II study of RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2 positive locally advanced muscle-invasive urothelial bladder cancer (Hope-03). J Clin Oncol 43(5_suppl):795–795. 10.1200/JCO.2025.43.5_suppl.795 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Lucianò R et al (2018) Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study. J Clin Oncol 36(34):3353–3360. 10.1200/JCO.18.01148 [DOI] [PubMed] [Google Scholar]
- 55.Van Dijk N, Gil-Jimenez A, Silina K, Hendricksen K, Smit LA, De Feijter JM et al (2020) Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat Med 26(12):1839–1844. 10.1038/s41591-020-1085-z [DOI] [PubMed] [Google Scholar]
- 56.Szabados B, Kockx M, Assaf ZJ, van Dam PJ, Rodriguez-Vida A, Duran I, et al. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. Eur Urol. 2022 Aug;82(2):212–22. (PMID: 35577646) 10.1016/j.eururo.2022.04.013 [DOI] [PubMed]
- 57.Vulsteke C, Kaimakliotis H, Danchaivijitr P, Sabadash MY, Rodriguez-Vida A, Zhang Z et al (2025) LBA2 Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: the phase III KEYNOTE-905 study. Ann Oncol 36:S1648. 10.1016/j.annonc.2025.09.124 [DOI] [Google Scholar]
- 58.Hoimes CJ, Galsky MD, Valderrama BP, Maruzzo M, Font A, Ciuleanu TE et al (2026) Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab for participants with muscle-invasive bladder cancer who are eligible for cisplatin: randomized, open-label, phase 3 KEYNOTE-B15 study. J Clin Oncol 44(16_suppl):4614–4614. 10.1200/JCO.2026.44.16_suppl.4614 [DOI] [Google Scholar]
- 59.Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E et al (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387(1):9–20. 10.1056/NEJMoa2203690 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Staudacher AH, Brown MP (2017) Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer 117(12):1736–1742. 10.1038/bjc.2017.367 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A (2023) Antibody–drug conjugates come of age in oncology. Nat Rev Drug Discov 22(8):641–661. 10.1038/s41573-023-00709-2 [DOI] [PubMed] [Google Scholar]
- 62.Scherrer E, Kang A, Bloudek LM, Koshkin VS (2022) HER2 expression in urothelial carcinoma, a systematic literature review. Front Oncol 12:1011885. 10.3389/fonc.2022.1011885 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Singla N, Christie A, Freifeld Y, Ghandour RA, Woldu SL, Clinton TN et al (2020) Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma. Urol Oncol 38(12):933.e7-933.e12. 10.1016/j.urolonc.2020.04.025 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Roessler N, Miszczyk M, Gontero P, Miyajima K, Inoue S, Alfarhan AR et al (2025) Assessing clinical complete response after neoadjuvant systemic therapy in muscle-invasive bladder cancer: a systematic review. World J Urol 44(1):65. 10.1007/s00345-025-06146-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Maiorano BA, Dizman N, Necchi A (2026) Contextualizing the development of anti-HER2 therapies for patients with advanced urothelial carcinoma. Eur Urol. 10.1016/j.eururo.2026.01.027 [DOI] [PubMed] [Google Scholar]
- 66.Powles TB, Grande E, Alimohamed N, Oliveira N, Sridhar SS, Drakaki A et al (2025) SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma. Future Oncol 21(21):2705–2712. 10.1080/14796694.2025.2535280 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Powles T et al (2026) RC48G001: a phase 2 study of disitamab vedotin in HER2-expressing previously treated advanced UC. J Clin Oncol 44(7_suppl):LBA631. 10.1200/JCO.2026.44.7_suppl.LBA631 [DOI]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
All data analyzed during this study are derived from previously published studies, which are cited in the manuscript. The extracted data supporting the findings of this meta-analysis are available within the article and its supplementary information files.
